Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

Summary

To assess the safety and tolerability of AMG 171 as single or multiple doses in subjects with obesity

Timeline

Start

2019-12-13

Primary completion

2021-09-10

Completion

2021-09-10

Outcome

Outcome not reported

Stopped: “Amgen determined the totality of the data does not support continuation of AMG 171 development program for treatment of Obesity. No safety concerns identified.”

Drugs

Indications